RUNX1 and acute myeloid leukemia: The evaluation of AML metabolic profiling has given also a fundamental contribution to the identification of various metabolic abnormalities in some AML subsets: identification of distinct metabolic features differentiating FLT3-ITD AMLs from FLT3-WT childhood AMLs [206]; identification of the peculiarities of amino acid metabolism of human AML stem cells [182]; identification of the creatine kinase pathway as a metabolic vulnerability in EVI1-positive AML [194]; analysis of the enhanced fatty acid and lipid metabolism in AMLs, particularly in IDH-mutant AMLs [265].